Your session is about to expire
← Back to Search
HPV Vaccine and Screening Strategy for Cervical Cancer
N/A
Recruiting
Led By Jane Montealegre, M D
Research Sponsored by M.D. Anderson Cancer Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Females; Age ≥30 years
Have no history of hysterectomy with removal of the cervix
Timeline
Screening 3 weeks
Treatment Varies
Follow Up through study completion; an average 1 year.
Awards & highlights
Study Summary
This trial found that HPV vaccine and cervical screening can help prevent cervical cancer.
Who is the study for?
This trial is for women aged 30 or older living in RGV who haven't had a Pap test in the last 3.5 years or a Pap/HPV co-test in the past 5.5 years, and have not been diagnosed with cervical cancer or severe cervical dysplasia. Participants must be able to understand English or Spanish, are not pregnant, and do not belong to vulnerable populations.Check my eligibility
What is being tested?
The study tests a community-based strategy called PRECEDE-PROCEED aimed at improving access to cervical cancer screening for early detection of potential disease caused by HPV.See study design
What are the potential side effects?
Since this trial focuses on a public health intervention rather than medication, it does not involve typical drug side effects. However, participants may experience discomfort during screening procedures.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am a woman aged 30 or older.
Select...
I have not had a hysterectomy that removed my cervix.
Select...
I have never had cervical cancer or severe abnormal cell changes.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ through study completion; an average 1 year.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~through study completion; an average 1 year.
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Trial Design
1Treatment groups
Experimental Treatment
Group I: PRECEDE-PROCEEDExperimental Treatment1 Intervention
To identify predisposing, enabling, and reinforcing factors that could influence women's decision to participate in self-sample HPV testing and diagnostic follow-up.
Find a Location
Who is running the clinical trial?
M.D. Anderson Cancer CenterLead Sponsor
2,977 Previous Clinical Trials
1,788,618 Total Patients Enrolled
Jane Montealegre, M DPrincipal InvestigatorM.D. Anderson Cancer Center
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
How many participants are being treated in this experiment?
"Affirmative. Clinicaltrials.gov attests to this trial's active recruitment status, which was first published on October 30th 2023 and has been recently modified the same day. This clinical study is currently enrolling 920 patients at a single research centre."
Answered by AI
Is this research endeavor actively seeking participants?
"Yes, clinicaltrials.gov currently lists the trial as actively recruiting volunteers. This research project first appeared on October 30th 2023 and has been updated since; with 920 patients sought from a single location."
Answered by AI
Share this study with friends
Copy Link
Messenger